Investment Analysts’ Recent Ratings Updates for Amicus Therapeutics (FOLD)

A number of research firms have changed their ratings and price targets for Amicus Therapeutics (NASDAQ: FOLD):

• 10/8/2025 – Amicus Therapeutics had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
• 10/6/2025 – Amicus Therapeutics was upgraded by analysts at Zacks Research from a “hold” rating to a “strong-buy” rating.
• 9/27/2025 – Amicus Therapeutics had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
• 9/20/2025 – Amicus Therapeutics was upgraded by analysts at Wall Street Zen from a “hold” rating to a “buy” rating.
• 9/18/2025 – Amicus Therapeutics was upgraded by analysts at Needham & Company LLC from a “hold” rating to a “buy” rating. They now have a $14.00 price target on the stock.
• 8/30/2025 – Amicus Therapeutics was downgraded by analysts at Wall Street Zen from a “buy” rating to a “hold” rating.

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.